Who are DCC-2618's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): imatinib (IM), Nilotinib, Imatinib, Imatinib (Glivec), Supportive care+Ripertamab, Inlyta, Letybo®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dcc-2618.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

DCC-2618 — Competitive Intelligence Brief

DCC-2618 (DCC-2618) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor. Area: Oncology.

phase 3 Tyrosine kinase inhibitor KIT, PDGFRA Oncology Small molecule Live · refreshed every 30 min

Target snapshot

DCC-2618 (DCC-2618) — Deciphera Pharmaceuticals, LLC. DCC-2618 is a tyrosine kinase inhibitor that targets KIT, PDGFRA, and other receptor tyrosine kinases involved in gastrointestinal stromal tumors and other malignancies.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DCC-2618 TARGET	DCC-2618	Deciphera Pharmaceuticals, LLC	phase 3	Tyrosine kinase inhibitor	KIT, PDGFRA
imatinib (IM)	imatinib (IM)	First Affiliated Hospital, Sun Yat-Sen University	marketed	Tyrosine kinase inhibitor	BCR-ABL, KIT, PDGFRA
Nilotinib, Imatinib	Nilotinib, Imatinib	Seoul St. Mary's Hospital	phase 3	Tyrosine kinase inhibitor (TKI)	BCR-ABL, KIT, PDGFRA
Imatinib (Glivec)	Imatinib (Glivec)	Dermatologic Cooperative Oncology Group	phase 3	Tyrosine kinase inhibitor	BCR-ABL, KIT, PDGFRA
Supportive care+Ripertamab	Supportive care+Ripertamab	Air Force Military Medical University, China	phase 3	tyrosine kinase inhibitor	KIT, PDGFRA
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
Letybo®	Letybo®	Yuvell	marketed	FLT3 inhibitor / multi-targeted tyrosine kinase inhibitor	FLT3, JAK2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor class)

Jiangsu HengRui Medicine Co., Ltd. · 5 drugs in this class
Centre Leon Berard · 2 drugs in this class
AB Science · 2 drugs in this class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
Betta Pharmaceuticals Co., Ltd. · 1 drug in this class
Angion Biomedica Corp · 1 drug in this class
Beijing InnoCare Pharma Tech Co., Ltd. · 1 drug in this class
Chang-Ming Huang, Prof. · 1 drug in this class
Deciphera Pharmaceuticals, LLC · 1 drug in this class
AstraZeneca · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DCC-2618 — Competitive Intelligence Brief. https://druglandscape.com/ci/dcc-2618. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab